Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > llumina and Oxford Nanopore Enter into Broad Commercialization Agreement

Abstract:
Single-Molecule DNA Sequencing System Promises Dramatic Improvement in Cost, Speed, Versatility, and Simplicity of Sequencing

llumina and Oxford Nanopore Enter into Broad Commercialization Agreement

SAN DIEGO, CA and OXFORD, UK | Posted on January 12th, 2009

Illumina (NASDAQ:ILMN) and Oxford Nanopore Technologies ("Oxford Nanopore") today announced a strategic alliance including a commercialization agreement and equity investment. Under the terms of the commercialization agreement, Illumina will exclusively market, sell, distribute, and service BASE™ Technology products developed by Oxford Nanopore for DNA sequencing into the research and diagnostic markets on a worldwide basis. Illumina and Oxford Nanopore will share profits generated from sales.

Oxford Nanopore's new generation sequencing system uses protein nanopores coupled with a processive enzyme. This system is designed for direct electrical identification of DNA bases at the single-molecule level, without the need for fluorescent labels. Currently in development, this technology has the potential to provide substantial advantages over current sequencing approaches, not only in speed and cost but also in simplicity and versatility of overall workflow. The removal of the traditional fluorescent labeling step and reduced burden of sample preparation are highly desirable in future generations of sequencing technology.

As part of the agreement, Illumina made an equity investment of $18.0 million (£11.8 million), which will be used to accelerate the development of BASETM Technology. Illumina has also agreed to make an additional equity investment upon the achievement of a specific technical milestone.

"Oxford Nanopore's technology holds tremendous promise to achieve the sub-$1,000 human genome," said Jay Flatley, President and CEO of Illumina. "Making electrical measurements of unmodified DNA removes the need for complex sample prep and the high-performance optics found in today's sequencing systems. We look forward to a long and productive partnership with Oxford Nanopore."

Oxford Nanopore's CEO, Dr Gordon Sanghera commented, "This alliance brings together today's commercial leader in the field and what we believe will be the future's best sequencing technology. The agreement reflects the rapid progress we have made in developing nanopore technology towards being the first label-free, single-molecule sequencing system. The partnership will enable us to further accelerate our development and enable broad commercialization through Illumina's significant commercial infrastructure."

####

About Illumina
Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of next-generation life-science tools and integrated systems for the analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery and clinical research, allow diseases to be detected earlier, and permit better choices of drugs for individual patients.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: this release may contain forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are Illumina's ability (i) to develop and commercialize further our BeadArray™, VeraCode®, and Solexa® technologies and to deploy new sequencing, gene expression, and genotyping products and applications for our technology platforms, (ii) to manufacture robust instrumentation and reagents technology, together with other factors detailed in our filings with the Securities and Exchange Commission including our recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. We disclaim any intent or obligation to update these forward-looking statements beyond the date of this release.

About Oxford Nanopore Technologies Ltd

Oxford Nanopore was founded in 2005 on the science of Professor Hagan Bayley of the University of Oxford. Since its inception, the Company has focused on developing the pioneering work of Professor Bayley into a mass producible biochip and reader system for molecular analysis. Nanopores have been researched for more than 15 years at a number of the world's most prestigious academic institutions including Harvard, MIT, NIST, the University of Massachusetts, Texas A&M University, and the University of Oxford.

BASETM (Bayley Sequencing) technology uses an adapted protein nanopore coupled with a processive exonuclease enzyme to sequence DNA. The enzyme cleaves individual bases from a strand of DNA, and sequentially introduces the bases into the aperture of the nanopore. An ionic current is continually flowing through the nanopore, and as individual bases travel through the nanopore, each one creates a characteristic disruption in this current. This signal is recorded electronically and interpreted to identify the DNA base. Recordings from multiple channels in parallel allows high-throughput sequencing of DNA.

The technology is label-free and sensitive at the single-molecule level, meaning that it removes the need for fluorescent labels, optical imaging and instrumentation, and the need for complex sample preparation including DNA amplification. By scaling up into a massively parallel sequencing process on an array chip, this method has the potential to deliver dramatic improvements in cost, speed, simplicity and versatility of sequencing.

For more information visit www.nanoporetech.com/sequences.

For more information, please click here

Contacts:
Illumina Media:
Maurissa Bornstein
Public Relations Manager
+1-858-332-4055


Investors:
Peter J. Fromen
Sr. Director
Investor Relations
+1 858.202.4507

or
Oxford Nanopore Technologies
Dr Gordon Sanghera
CEO
Zoe McDougall
Communications
+44 870 486 1966

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Observing biological nanotransporters: Chemistry April 19th, 2018

Grand Opening of UC Irvine Materials Research Institute (IMRI) to Spotlight JEOL Center for Nanoscale Solutions: Renowned Materials Scientists to Present at the 1st International Symposium on Advanced Microscopy and Spectroscopy (ISAMS) April 18th, 2018

Salt boosts creation of 2-D materials: Rice University scientists show how salt lowers reaction temperatures to make novel materials April 18th, 2018

Individual impurity atoms detectable in graphene April 18th, 2018

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

180 Degree Capital Corp. Reports Net Asset Value per Share of $2.60 as of December 31, 2017; A Decrease of 3.0% From Prior Quarter and an Increase of 11.1% From December 31, 2016 February 27th, 2018

Nanowire LED Innovator Aledia Announces €30 ($36M) Million Series-C Financing: Intel Capital Joins Existing Investors to Commercialize Certain Nanowire-LED Technologies for Mobile Displays January 29th, 2018

180 Degree Capital Corp. Leads Investment in TheStreet, Inc.; Investment Enables Removal of Capital Structure Overhang November 14th, 2017

180 Degree Capital Corp. Appoints Investment Banking Veteran Parker Weil to Its Board of Directors August 2nd, 2017

Nanomedicine

Observing biological nanotransporters: Chemistry April 19th, 2018

Nanobiotix Shows NBTXR3 Nanoparticles Can Stoke Anti-Tumor Immune Response April 17th, 2018

Tiny nanomachine successfully completes test drive: Researchers at the University of Bonn and the research institute Caesar build a one-wheeled vehicle out of DNA rings April 11th, 2018

Bloodless revolution in diabetes monitoring: Scientists have created a non-invasive, adhesive patch, which promises the measurement of glucose levels through the skin without a finger-prick blood test April 10th, 2018

Announcements

Observing biological nanotransporters: Chemistry April 19th, 2018

Grand Opening of UC Irvine Materials Research Institute (IMRI) to Spotlight JEOL Center for Nanoscale Solutions: Renowned Materials Scientists to Present at the 1st International Symposium on Advanced Microscopy and Spectroscopy (ISAMS) April 18th, 2018

Salt boosts creation of 2-D materials: Rice University scientists show how salt lowers reaction temperatures to make novel materials April 18th, 2018

Individual impurity atoms detectable in graphene April 18th, 2018

Alliances/Trade associations/Partnerships/Distributorships

New era in high field superconducting magnets – opening new frontiers in science, nanotechnology and materials discovery January 9th, 2018

Leti Field Trials Demonstrate New Multicarrier Waveform for Rural, Maritime Broadband Radio: Field Trial in Orkney Islands Used New Filtered Multicarrier Waveform at 700MHz Band with Flexible Bandwidth Usage (Fragmented and Continuous Spectrum) December 18th, 2017

A new product to help combat mouldy walls, thanks to technology developed at the ICN2 December 14th, 2017

JPK Instruments announce partnership with Swiss company, Cytosurge AG. The partnership makes Cytosurge’s FluidFM® technology available on the JPK NanoWizard® AFM platform December 8th, 2017

New-Contracts/Sales/Customers

Deep Space Industries to provide Comet satellite propulsion for BlackSky, LeoStella April 3rd, 2018

STMicroelectronics Selects GLOBALFOUNDRIES 22FDX® to Extend Its FD-SOI Platform and Technology Leadership : GF’s FDX technology will enable ST to deliver high-performance, low-power products for next-generation consumer and industrial applications January 9th, 2018

Solid State Laser manufacturer Lasertel Inc. purchases an Oxford Instruments ICPCVD advanced deposition solution for improved device performance November 3rd, 2017

GLOBALFOUNDRIES and Soitec Enter Into Long-term Supply Agreement on FD-SOI Wafers: Strategic milestone to help guarantee a secure, high-volume supply of FD-SOI technology September 20th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project